FIELD: medicine; oncology.
SUBSTANCE: group of inventions is intended for the treatment of castration-resistant prostate cancer. The antitumor agent includes the compound represented by formula (I) or a pharmaceutically acceptable salt thereof in a dose which, based on the free form of compound I, is from 150 mg to 450 mg. This medicinal product is intended for use in combination with abiraterone or its derivative for the treatment of castration-resistant prostate cancer with bone metastases. The abiraterone derivative is selected from the group consisting of acid esters, alkyl esters, carbonates and carbamates. Also the use of this agent as an active agent to enhance the antitumor effect of abiraterone or its derivative for the treatment of castration-resistant prostate cancer with bone metastases is presented. In addition, the use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in combination with abiraterone or a derivative thereof for the treatment of castration-resistant prostate cancer with bone metastases is disclosed.
EFFECT: use of the invention provides treatment for castration-resistant prostate cancer with bone metastases.
19 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION TREATMENT OF CANCER | 2012 |
|
RU2640485C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING AGENTS (SARD) AND METHODS OF USING THEREOF | 2016 |
|
RU2724103C2 |
| COMBINATION, USE THEREOF AND METHOD OF TREATING | 2017 |
|
RU2731535C1 |
| COMBINATION FOR TREATING PROSTATE CANCER, A PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATING | 2017 |
|
RU2733950C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING PROSTATE CANCER, USING BENZOHETEROCYCLIC COMPOUND AND METHOD FOR PREVENTING AND/OR TREATING PROSTATE CANCER | 2016 |
|
RU2705576C2 |
| COMBINATION TREATMENT | 2014 |
|
RU2666999C2 |
| USE OF 4-PYRIDYLMETHYLPHTHALAZINES IN CANCER TREATMENT | 2002 |
|
RU2320344C2 |
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING (SARD) LIGANDS AND METHODS OF USING THEM | 2016 |
|
RU2689988C2 |
